Viela Adds Momentum To Burgeoning NMOSD Market With Pivotal Inebilizumab Results

 
• By Jo Shorthouse
Bike rider
Viela's N-MOmentum trial results look to add treatment options for neuromyelitis optica patients • Source: Shutterstock

More from Clinical Trials

More from R&D